Detailed Agenda

Time Agenda
1.30pm
Registration & welcome coffee
2.00pm
Opening message
By Holger Kirchner, MD Exyte Central Europe GmbH, Stuttgart, Germany
2.15pm
Biopharmaceuticals 2100 - The future is today
By Prof. Dr. Christoph Herwig, TU Wien, Austria

Future medications challenge us today. We need more efficient treatments for enhanced life quality, which reaches everybody. We need to project our knowledge of biopharma commodity processes on personalized medicine, which is deployed decentrally and globally. This contribution provides a current view on what we have learnt in R&D and a vision how future treatments on the year 2100 may look like. We will name technological enablers and current gaps to this vision. Exiting times are in front of us after decades of research.

2.45pm
Accelerating growth in pharma and clinical nutrition markets
By Dr. Frank Wartenberg, IQVIA, EMEA, Frankfurt, Germany

Key elements in the life sciences ecosystem are evolving. Market growth is expected to moderate in certain therapeutic areas and accelerate in others. A number of key forces are reshaping the ecosystem including public health objectives, consumer engagement, innovative channel options, and shifting treatment options. How should players prepare to win? What alternate future awaits firms who do not reposition effectively? Presentation will focus on where to play, how to win and capabilities required going forward

3.15pm
Bio-Pharmaceutical location strategy in a dynamic market
By Woody Hydrick, WH-Consulting, USA

In his speech we will hear about recent international investment trends in the GMP driven industry. How decisions are made by the biopharmaceutical industry and which and what kind of countries and clusters doing to attract these investments. We will hear also about new trends in manufacturing and partnering as well in M&A's of MNC and midsize companies. A substantial information will highlight the development of new trends in the GMP arena such as firms "going west" i.e. moving from China to EMEA or US and future expectations.

3.45pm
Tea and coffee break
4.15pm
From prefabricated facility modules to standard construction cells: flexible and fast GMP Plants
By Luca Mussati, Vice President Life Science Chemicals, Exyte GBU-LSC, Stuttgart, Germany

In an international market place of the GMP driven industry, quality, costs and time are the key factors. Modern facility concepts are required to match with changing market demands. Construction times and sequences for green for brown field projects are always a challenge for all investors and direct involved responsible. Modern facility solutions will cover new facilities and revamp areas. Long engineering and construction times can be shorten by advanced and pre-engineered solutions. The speech will cover all aspects required for a successful project and necessary interfaces.

4.45pm
Ballroom manufacturing in cell and gene therapy – the importance of a manufacturing platform approach
By Dr. Oliver Bartelsen, Global Head of Business Development and Industrial Services, Miltenyi Biotec GmbH, Bergisch Gladbach, Germany

We will learn about latest technology and trends in the R+D in the field of cell and gene therapy technology. How to develop, transform and implement a new platform based technology into an industrial production. Implementation of a flexible GMP facility for production of autologous cell and gene therapy products to meet international standards, requirements, budget and quality. Flexibility and lean are main drivers but also to be competitive in the global market place.

5.15pm
Panel discussion
Moderation by Prof. Dr. Christoph Herwig

The panel discussion will engage and involve all speakers and valued guests. It will be an open discussion and exchange of views of all presented topics. We like to seek for answers on future requirements considering an increase demand on process validation and still meet economic opportunities. Hence, we want to revisit current showstoppers and identify major technological, societal etc. enablers on how cost of goods and speed to market can be competitively handled within modern complex GMP production facilities.

5.45pm
Closing message
By Francois Abiven, President of Exyte GBU-LSC, Stuttgart, Germany
6.00pm
Networking event at restaurant, Hyperion Hotel, same level as event venue.